Efficacy and Safety of Neoadjuvant Treatment with Bevacizumab, Liposomal Doxorubicin, Cyclophosphamide and Paclitaxel Combination in Locally/Regionally Advanced, HER2-Negative, Grade III at Premenopausal Status Breast Cancer: A Phase II Study.

CONCLUSION: PLAC-B as neoadjuvant treatment of this subpopulation with TNBC and ER/PR+ patients is effective and safe. Further studies are necessitated.
PMID: 29744672 [PubMed - as supplied by publisher]

Source: Clinical Breast Cancer - May 9, 2018 Category: Cancer & Oncology Authors: Tampaki EC, Tampakis A, Alifieris CE, Krikelis D, Pazaiti A, Kontos M, Trafalis DT Tags: Clin Drug Investig Source Type: research